<DOC>
	<DOCNO>NCT01171755</DOCNO>
	<brief_summary>In current study , evaluate efficacy gemcitabine TS-1 combination chemotherapy advance BTC .</brief_summary>
	<brief_title>Phase II Study Gemcitabine TS-1 Biliary Trat Cancer</brief_title>
	<detailed_description>At present , surgery curative treatment option biliary tract cancer ( BTC ) . However , less 25 % patient resectable presentation high relapse rate surgery . Because low incidence heterogeneity BTC , clinical trial difficult conduct patient , hamper evaluation optimal chemotherapy regimen . Owing lack randomized phase III study , standard regimen palliative chemotherapy GBC CC . But exploration optimal regimen standard first-line chemotherapy BTC imperative order improve survival patient . Gemcitabine demonstrate antitumor activity monotherapy phase II trial BTC patient response rate range 22 36 % ( 2001 Proc Am Soc Clin Oncol 20 : A626 , 2001 J Clin Oncol 19 ( 20 ) :4089-4091 , 2001 Ann Oncol 12 ( 2 ) :183-186 ) . As gastrointestinal tumor , 5-fluorouracil ( 5-FU ) study drug single agent combination different dosage schedule response rate 10-20 % median survival 7-9 month BTC ( 2005 Cancer 103:111-118 , 2001 Clin Cancer Res 7:3375-3380 ) . The combination gemcitabine fluoropyrimidine biliary cancer worthy evaluation . The toxicity profile agent know non-overlapping , combination well tolerate . Oral fluoropyrimidines consider alternative conventional protract 5-FU infusion far provide comparable efficacy compliance . S-1 oral fluoropyrimidine preparation develop Taiho Pharmaceutical Co. , Ltd. ( Tokyo , Japan ) combine tegafur two 5-FU modulators , 5-chloro-2 , 4-dihydroxypyridine ( CDHP ) potassium oxonate ( Oxo ) , molar ratio 1:0.4:1 . Tegafur , prodrug 5-FU , convert 5-FU mainly liver tumor cell . CDHP , reversible inhibitor dihydropyrimidine dehydrogenase , suppress degradation 5-FU , thereby maintain high concentration 5-FU plasma tumor cell . CDHP also decrease cardiotoxic neurotoxic effect reduce production F-b-alanine ( FBAL ) , main catabolite 5-FU . Several phase II trial show TS-1 monotherapy combination CDDP , paclitaxel irinotecan effective palliative treatment option advance gastric cancer colorectal cancer . In current study , evaluate efficacy gemcitabine TS-1 combination chemotherapy advance BTC .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Pathologically proven , measurable , unresectable , locally advanced metastatic adenocarcinoma arise intra extrahepatic biliary duct gallbladder papilla Vater 2 . No prior chemotherapy advance disease allow 3 . No concurrent radiotherapy 4 . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) 5 . At least 18 year old 6 . ECOG performance status ≤ 2 7 . Adequate organ function evidence follow ; Absolute neutophil count &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L ; hemoglobin &gt; 10g/dL ; INR ≤ 1.4 ; total bilirubin ≤1.5 UNL ; AST and/or ALT &lt; 5 UNL ; albumin &gt; 3g/dL &gt; 30µmol/L ; creatinine clearance ≥ 50mL/minInformed consent sign 8 . Subject able comply schedule followup management toxicity 1 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption TS1 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) 2 . Subject reproductive potential ( male female ) use adequate contraceptive measure 3 . Pregnancy breastfeed 4 . Other serious illness medical condition , notably heart lung failure , active uncontrolled infection ( infection require antibiotic ) 5 . History significant cardiac disease , arrhythmias angina pectoris 6 . Past concurrent history neoplasm , except curatively treat basal cell skin cancer adequately treat insitu carcinoma cervix 7 . Other concomitant anticancer agent 8 . Subjects regularly follow psychological , social , familial geographic reason 9 . Patients use investigational agent receive investigational drug ≤ 4 week prior first study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>